Sun aims to strongarm Taro shareholders

India's Sun Pharmaceuticals just won't take no for an answer. After its merger deal with Israel's Taro Pharmaceuticals fell apart last month, Sun now says it's going to try to force the company's controlling shareholders to sell out. "We will do everything required to preserve our rights," Sun's chairman said in a statement. Both companies are suing over the collapsed deal. Report

Suggested Articles

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Intent-driven audiences are inspired to make health-improving changes after a positive online experience. Find out what they’re driven to do.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.